Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent…
Biotechnology
US, Boston [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -22.05 | 4.35 | 5.58 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -75.54 | -0.39 | 1.61 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -64.29 | 1.02 | 2.87 | |
| Cash | -28.19 | 3.35 | 4.66 | |
| Capex | 3937891.10 | -0.67 | < 0.005 | |
| Free Cash Flow | -170.54 | -1.34 | -0.50 | |
| Revenue | 5.49 | 0.43 | 0.41 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 2.07 | 0.88 | 0.87 | |
| Operating Margin | -216.37 | -5.39 | -1.70 | |
| ROA | -336.84 | -0.55 | -0.13 | |
| ROE | -836.08 | -2.30 | -0.25 | |
| ROIC | -240.66 | -0.83 | -0.24 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of RYTM is permitted for members.
5
Growth
The "Growth Entry" for the Focus of RYTM is permitted for members.
6
Leverage & Liquidity